This interview with a US-based key opinion leader (KOL) provides insights into the evolving disease landscape for non-alcoholic steatohepatitis (NASH). The discussion includes prescribing experience with Madrigal Pharmaceuticals’ Rezdiffra, the early adoption of Novo Nordisk’s Wegovy following its expanded indication, and perspectives on emerging therapeutic classes with emphasis on FGF21 analogs and incretins and their impact on clinical practice. Key assets highlighted include Inventiva Pharma’s lanifibranor, Akero Therapeutics’ efruxifermin, and 89bio’s pegozafermin, Eli Lilly’s tirzepatide, and Boehringer Ingelheim’s survodutide.

This interview was conducted on 13 March 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.